Rice bioengineers shed light on dosing challenges for cancer immunotherapy
November 06, 2024
November 06, 2024
HOUSTON, Texas, Nov. 6 -- Rice University issued the following news release:
Oleg Igoshin (left) and Jonathon DeBonis (Photo by Jeff Fitlow/Rice University)A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) a potent immune-boosting protein that holds promise for cancer treatment loses effectiveness over time when used as an immunotherapeutic. The research challenges long-held assumptions about IL-12's behavior in the . . .
Oleg Igoshin (left) and Jonathon DeBonis (Photo by Jeff Fitlow/Rice University)A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) a potent immune-boosting protein that holds promise for cancer treatment loses effectiveness over time when used as an immunotherapeutic. The research challenges long-held assumptions about IL-12's behavior in the . . .